We use advanced cellular and molecular biology techniques on our automated platform to validate novel targets. Our approach is driven by our team’s scientific rigor and expertise coupled with technical excellence in fully automated experiment execution and data analysis, leading to faster progression into the next development stage.
We deploy both the latest in silico and well-established in vitro screening approaches to identify novel developable drug-like matter. This unique pairing of computational techniques (virtual screens, ML-guided molecule selection) and wet lab automation generates high quality hits faster and more efficiently compared to conventional approaches.
We deliver rigorous validation and profiling of hits, with Ulysses enabling rich and detailed, quantitative structure-activity relationship (QSAR) mapping, as well as selectivity, kinetic and mechanism of action studies. Our platform returns a comprehensive evaluation of hits, enabling effective and reliable prioritization for progression to lead series.
Ulysses delivers accelerated lead optimization by drastically shortening the DMTA cycle time. High reliability precision data generated on our platform drives confident iteration through to candidate selection in a fraction of the time usually required. We continuously develop our library of pragmatic and elucidating assay cascades, leading to superior drug design and enhanced success rates.
En route to IND, comprehensive pharmacokinetics and pharmacodynamics studies and safety/ toxicology assessments are conducted. These involve both in vitro and in vivo studies, conducted in full compliance with all necessary regulatory requirements – bringing better drugs to patients sooner.